AIM ImmunoTech Inc.
AIM · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 4% | 56.3% | -64.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | -$0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -369.2% | 60% | 37.5% | 213.3% |
| R&D Expenses | $1 | $1 | $1 | $2 |
| G&A Expenses | $2 | $1 | $3 | $4 |
| SG&A Expenses | $2 | $1 | $3 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $3 | $4 | $6 |
| Operating Income | -$2 | -$3 | -$4 | -$6 |
| % Margin | -9,096.2% | -10,584% | -22,618.8% | -13,011.1% |
| Other Income/Exp. Net | -$1 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$3 | -$3 | -$4 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | -$3 | -$4 | -$6 |
| % Margin | -12,630.8% | -11,176% | -23,156.3% | -13,260% |
| EPS | -1,568.71 | -3.68 | -0.05 | -0.1 |
| % Growth | -42,528% | -7,260% | 50% | – |
| EPS Diluted | -1,568.71 | -3.68 | -0.05 | -0.1 |
| Weighted Avg Shares Out | 0 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 0 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $0 | $0 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$3 | -$3 | -$6 |
| % Margin | -11,853.8% | -10,360% | -21,618.8% | -12,824.4% |